The purpose of this study is to evaluate the feasibility of and treatment plans for helical tomotherapy (HT) for solitary lung tumors. Nine patients with stage ІA non-small-cell lung cancer (NSCLC) and three patients with solitary lung metastasis were treated with HT. All patients were immobilized with the BodyFIX system, and the target volume shown on computed tomography in the 3 respiration phases were superimposed onto the 3-dimensional radiation treatment planning system to represent the internal target motion. All patients were treated with 54-60 Gy in 12 fractions over 8 to 13days. The median follow-up time was 14 months (range: 3-16 months). The overall response rate was 92%. The local control rate at 1 year was 100% with no difference between NSCLC and metastasis. Of 12 patients, one patient experienced Grade 2 radiation pneumonitis (RP), and the other patient with severe interstitial pneumonia and emphysema experienced Grade 5 RP. The mean lung dose (MLD) and the dose-volume histogram (DVH) for the normal lung volumes were converted into normalized total dose with an α/β ratio of 3 Gy. The DVH of the normal lung volumes demonstrated that the mean volumes of V 10 , V 30 , V 50 , and V 70 were 40.4 ± 9.4%, 21.3 ± 6.4%, and 12.8 ± 4.6%, and 9.3 ± 4.2% in all patients, 28.8%, 18.7%, 12.3%, and 10.5% in the patient with Grade 2 RP, and 29.3%, 17.9%, 7.7%, and 5.4% in the patient with Grade 5 RP. The mean MLD of all patients was 13.5 ± 3.9 Gy, and those values of patients with Grade 2 and 5 RP were 12.9 and 21.8 Gy, respectively. Our study found that only the MLD was significantly correlated with RP ≥Grade 2 (p = 0.030) using the Student's t-test. Our study found the conformity index value of 1.48 ± 0.15 and the homogeneity index value of 1.066 ± 0.023, which suggested the feasibility of using HT to treat lung tumors with hypofractionation. In conclusion, HT is a feasible non-invasive technique for treating solitary lung tumors and achieves high accuracy in terms of dose conformity and homogeneity.
Introduction
The incidence of lung cancer is increasing in Japan as it is in the rest of the world. The detection of early-stage lung cancer has also been increasing due to the routine use of computed tomography (CT). Surgical resection of stage I non-small-cell lung cancer (NSCLC) results in 5-year survival rates of approximately 60-70% (1-3) and remains the standard therapy for this population. However, some patients with stage I NSCLC are medically inoperable because of their comorbidities such as chronic obstructive pulmonary disease with emphysema, severe cardiovascular disease, or other medical conditions. In addition, some patients refuse surgery for personal reasons such as fear. These inoperable patients were often treated with conventional radiotherapy techniques such as parallelopposed anterior-posterior fields. However, the 5-year survival rate due to conventional radiotherapy was approximately 15%, and local control rates were also poor (4). In this context, stereotactic radiotherapy (SRT) has increasingly been used in clinical settings and has shown clinical benefit in patients with stage I NSCLC (5-7). This new technique generally employs multiple arcs or fixed beams from a linear accelerator (Linac). However, severe toxicity has been reported for Linac-based SRT. Timmerman et al., reported that a regimen of 60 to 66 Gy total in three fractions should not be used for patients with tumors near the central airways due to excessive toxicity (8). In addition, multiple Phase I and II SRT studies of the treatment of stage I-II NSCLC have reported chest wall (CW) pain and/or rib fractures (9) (10) (11) . Therefore, a more advantageous technique such as intensity-modulated radiotherapy (IMRT), which can deliver higher radiation doses to the lesion while sparing the organs at risk (OAR), is warranted in order to avoid the severe toxicity of other regimens.
Helical tomotherapy (HT) is a novel IMRT treatment modality. HT is a form of 3D conformal radiation therapy in which treatment beams are spatially and temporally modulated to maximize the dose delivered to the tumor while minimizing the dose delivered to normal structures (12). In addition, detectors within the tomotherapy system provide megavoltage computed tomographic (MVCT) images of the patient, which can be obtained immediately before treatment for setup, registration, and repositioning (13, 14) . Thus, HT is considered to be comparable to other stereotactic irradiation techniques such as Linac-based SRT in terms of its stereotaxis and dose conformity (15) (16) (17) . We believe that HT provides excellent target coverage with dose uniformity while sparing the organs at risk (OAR) and would avoid severe toxicity in patients with a solitary lung tumor. Therefore, we implemented HT for patients with a solitary lung tumor such as primary lung cancer or solitary lung metastasis. The present paper reports on the feasibility of HT in patients with a solitary lung tumor and the dosimetric evaluation of these radiation treatment plans.
Materials and Methods

Patient Characteristics
Between May 2008 and June 2009, 12 patients with a solitary lung tumor were treated with HT at Aichi Cancer Center Hospital or Kizawa Memorial Hospital. The 18-fluoro-2deoxyglucose positron emission tomography (FDG-PET) was performed in all patients before treatment. The patient and tumor characteristics are shown in Table I . NSCLC was the most common primary lesion and all patients' clinical stage were stage IA except one stage IV patient; i.e., T1N0M1, which involved solitary bone metastasis. There were three patients who had lung lesions highly suggestive of lung cancer but who refused to have their lung cancer diagnosed pathologically. Among three patients whose solitary lung metastases were treated, none had active disease, except for In the tomotherapy treatment conditions, a 2.5-cm field width (FW) was used in all patients. Other common parameters were a pitch of 0.3 and a normal modulation factor of 2.0. The inverse planning system performed a variable number of iterations, which ranged from 50 to 300, during the optimization process for each plan. The mean treatment beam-on time was 6.2 ± 1.1 min for all treatment plans. All patients began treatment with daily MVCT acquisitions for setup verification.
Plan Comparison Criteria
To correct for the effect of dose per fraction, the mean lung dose (MLD) and the DVH for the normal lung volumes were converted into the 2 Gy equivalent normalized total dose (EQD 2 ) using the linear quadratic model with an α/β ratio of 3 Gy. We analyzed the DVH for the normal lung volumes receiving 10 Gy in EQD 2 (V 10 ), 30 Gy in EQD 2 (V 30 ),  50 Gy in EQD 2 (V 50 ), and 70 Gy in EQD 2 (V 70 ). We used the conformity index (CI) and the homogeneity index (HI) for DVH analysis of the PTV. The CI was defined as the ratio of the treated volume within the prescription isodose surface (VTV) to the PTV (VPTV): CI = VTV/VPTV. The HI was defined as the ratio of the maximal dose in the PTV (D max ) to the prescription dose (DR x ): HI = D max / DR x (18, 19) . The volume of the CW receiving 35 Gy was also calculated when a patient was considered to be at risk of developing CW pain and/or rib fractures as defined by lesions within 2.5 cm of the CW receiving a >20 Gy maximal point dose to the adjacent CW (20). Analyses were performed using the Student's t-test to determine if there was a significant difference in any of the parameters examined. Differences were considered statistically significant at p  0.05.
Follow-up
Follow-up evaluations after treatment were performed at intervals of one month, and chest CT were carried out at intervals of 2 months. The best response was evaluated by comparing our radiological findings with the pretreatment imaging and was classified in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) (21). Complications were graded in accordance with the National Cancer Institute's Common Toxicity Criteria, version 3.0 (22). Overall survival as well as local tumor control were calculated using Kaplan-Meier estimates.
the solitary lung metastasis treated with HT, that was defined as an uncontrolled primary tumor or metastasis. Any patients did not receive chemotherapy in combination with HT.
Treatment Planning
All patients were immobilized in a supine position with the BodyFIX system (Medical Intelligence, Schwabmuenchen, Germany) and simulated by computed tomography (CT) with a 2.5-mm slice thickness. The first CT scan was performed under normal breathing. Then, 4 additional scans were performed with breath holding during the expiratory and inspiratory phases twice each. The outlines of the target were delineated on a 3-dimensional radiation treatment planning system (Pinnacle 3 workstation, Hitachi Medical Corporation, Tokyo, Japan) using the lung CT window setting; i.e., window width: 1300 Hounsfield units (HU) and window level: -350 HU. The clinical target volume (CTV) was defined as the visible gross tumor volume (GTV) with an additional margin of 3 to 5 mm. The CTV shown on CT in the 3 phases were superimposed onto the 3-dimensional radiation treatment planning system to represent the internal target volume (ITV). The ITV was expanded symmetrically by 2 mm in all dimensions to create the planning target volume (PTV). All patients were treated with 60 Gy in 12 fractions over 8 days (10 Gy per day, 5 Gy per fraction, with no interval between the fractions). For the first patient only, the PTV received 54 Gy in 12 fractions over 13 days (4.5 Gy per fraction, with no interval between the fractions).
Normal structures including the spinal cord, esophagus, lung, trachea and bronchus, brachial plexus, pulmonary artery, stomach, and other normal structures (e.g., the chest wall) were considered to be OAR if they were close to the PTV. Planning organs at risk volumes (PRV) were also used, and the spinal cord PRV was defined as a three-dimensional margin 3 mm larger than the spinal cord to ensure that the PRV margin at least covered all portions of the spinal cord. The PRV of the esophagus, trachea and bronchus, and stomach were defined as 5 mm larger in all directions than the corresponding structure. The lung on the dose-volume histogram (DVH) was defined as the lung minus the PTV. The CT images and structure sets were transferred to the Tomotherapy Hi-Art System workstation (TomoTherapy Inc., Madison, WI, USA). Normal structures were constrained on an individual basis using maximum and DVH dose constraints without compromising the PTV coverage with 95% of the PTV receiving the minimum prescribed dose. The dose constraints required to achieve an acceptable HT plan were as follows: (1) site was the larynx, developed a new lung metastasis and cervical lymph node metastasis 3 months after treatment with HT. One patient died of the exacerbation of interstitial pneumonia 8 months after treatment with HT. The overall survival rate was 89% at 1 year.
Complications
No acute complications were observed. Grade 1 atelectasis was observed on CT in two patients 8 and 12 months after treatment with HT, respectively. There were two late complications accompanied by symptoms. One patient experienced Grade 5 radiation pneumonitis (RP); however, this patient had severe interstitial pneumonia and chronic obstructive pulmonary disease with emphysema before treatment and was in a poor clinical condition (performance status = 2). The patient's interstitial pneumonia was exacerbated gradually after HT treatment, and died 8 months after HT treatment. The other patient experienced Grade 2 RP 3 months after treatment, but he recovered immediately due to short-term oral steroid administration. In fact, this patient had previously undergone lung irradiation near to RT field of HT when he was treated with Linac for advanced laryngeal cancer and
Results
Tumor Control, Survival, and Cause of death Seven patients showed a complete response (CR), 4 showed a partial response (PR), one showed stable disease, and no patient showed progressive disease. The overall response rate including CR and PR was 92%. Figure 1 shows the DVH and dose distributions of a patient who had a lung lesion highly suggestive of lung cancer in the left superior lobe. This patient obtained a CR (Figure 2) , and the local tumor was controlled without late complications at 11 months after the completion of treatment. Figures 1 and 2 Of the 12 patients, one patient was dead at the time of analysis. The median follow-up time from treatment with HT was 14 months (range: 3-16 months). No patient developed local recurrence after treatment. The local control rate was 100% at 1 year with no difference between NSCLC and metastasis. Two patients treated with HT for solitary lung metastasis developed new metastases. One patient, whose primary site was the uterine cervix, developed hilar lymph node metastasis near to the solitary lung metastasis in the right superior lobe 13 months after treatment with HT. The other patient, whose primary figure 1: Example of isodose distribution and dose volume histograms using helical tomotherapy for a patient with a lung lesion that was highly suggestive of lung cancer in the left superior lobe.
had his supraclavicular fossa irradiated. No other late complications including CW pain or rib fractures were observed, although the follow-up time was not very long.
Treatment Plan Analysis and Correlation with Complications
The mean ± standard deviation (SD) for the CI value was 1.48 ± 0.15. Similarly, the mean HI value was 1.066 ± 0.023. The volume of the CW receiving 35 Gy was calculated in 6 patients who were considered to be at risk of developing CW pain and/or rib fractures as defined above. The mean volume of the CW receiving 35 Gy was 21.9 ± 21.4 cc.
The DVH of the normal lung volumes demonstrated that the mean volumes of V 10 , V 30 , V 50 , and V 70 were 40.4 ± 9.4%, 21.3 ± 6.4%, and 12.8 ± 4.6%, and 9.3 ± 4.2% in all patients, 28.8%, 18.7%, 12.3%, and 10.5% in the patient with Grade 2 pulmonary complication, and 29.3%, 17.9%, 7.7%, and 5.4%
in the patient with Grade 5 pulmonary complication. The mean MLD of all patients was 13.5 ± 3.9 Gy, and those values of patients with Grade 2 and 5 pulmonary complications were 12.9 and 21.8 Gy in EQD 2 , respectively. Table II shows the relationship between RT plan (PTV volume, lung volume, V 10 , V 30 , V 50 , V 70 , and MLD) and pulmonary complication. Table II The correlation between the normal lung volume receiving each dose and pulmonary complications of  Grade 2 was investigated using the Student's t-test. There was no significant correlation between pulmonary complications of  Grade 2 and V 10 , V 30 , V 50 , or V 70 (p = 0.06, 0.49, 0.38, and 0.63, respectively); however, MLD was significantly correlated with pulmonary complications  Grade 2 (p = 0.030).
Discussion
Recently, HT has become available as a new and promising delivery method for IMRT. During HT delivery a radiation fan 13.5 -7 12.9 Grade 2 8 9.5 -9
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The numbers in parentheses indicate the range. RT, radiotherapy, SD, standard deviation, V 10, the normal lung volumes receiving 10. Gy in EQD 2 (2 Gy equivalent normalized total dose), MLD, mean lung dose, PTV, planning target volume.
beam of 6 MV photons rotates around the patient while the patient slowly moves through the gantry. This results in a helical beam trajectory from the patient's perspective. The photon fluence in different sections of the fan beam is modulated by a binary multi leaf collimator (MLC). The MLC configuration is optimized and varied as a function of the gantry angle using an inverse treatment planning process, which allows the delivery of highly conformal radiation doses to a target. The CI value is a good quality measure because it accounts for spatial deviations as well as the conformity between the prescription isodose and target volume. Our study found a CI value of 1.48 ± 0.15 and a HI value of 1.066 ± 0.023, which suggested the feasibility of using SRT to treat lung tumors with hypofractionation (23).
Recently, Lee at al., reported their early clinical experience and outcome of HT even for multiple metastatic lesions (24).
Using a linear-quadratic model, the biologic effective dose (BED) was here defined to be nd (1 + d/α/β ratio) Gy, where n is the fractionation number, d is the daily dose, and the α/β ratio was assumed to be 10 for tumors. Since our regimen of 10 Gy with 5 Gy per fraction with no interval between the fractions was biologically equal to 10 Gy per fraction, the value of our regimen was 120 Gy-BED for tumors. Because the recommendation of >100 Gy-BED for local control has been reported by several groups (5, 6), we used these dose fractionation schedules. On the other hand, the dose specification for normal tissues was basically derived from a phase II study of SRT for stage IA NSCLC of the Japan Clinical Oncology Group (JCOG 0403). JCOG 0403 (25) selected 48 Gy in four fractions over 4 to 8 days, the value was 336 Gy-BED with the α/β ratio of 2 for normal tissues. The value of our dose fractionation schedules was 360 Gy-BED with the α/β ratio of 2. Since both regimens have approximately the same BED for normal tissues, in principle, we used the dose specification of JCOG 0403.
Many studies of Linac-based SRT in the treatment of earlystage NSCLC and pulmonary metastasis have been reported (26) (27) (28) . Table III On the other hand, there were a few studies regarding HT for a lung tumor, as also summarized in Table III (29) (30) (31) . Hodge et al., (29) and Baisden et al., (30) reported their early experiences of HT for stage I NSCLC.
In their reports, there was no evidence of local recurrence with very short follow-up. Our study also showed an excellent local control rate of 100% at 1 year with a median follow-up of 14 months. Kim et al., reported their experience with HT for simultaneous multitarget radiotherapy in patients with multiple pulmonary metastases (31). The median doses prescribed were 50 Gy and 40 Gy delivered in 10 fractions over 2 weeks to the 95% isodose volume of the GTV and the PTV, respectively. The rate of local tumor control was 87% with a median follow-up of 13 months. Interpretation of results reported by Kim et al., is rather difficult, since their study involved patients with multiple pulmonary metastases.
As for complications, no CW pain or rib fractures were observed, although the follow-up time was not very long. The development of CW toxicity is clinically relevant. A recent study demonstrated that the CW volume receiving 20 Gy should be limited to < 55 cc with the regimen of 60 Gy in 3 fractions, if possible, to reduce the risk of toxicity without compromising tumor coverage (20) . Given the correction for the effect of dose per fraction using EQD 2 with an α/β ratio of 3 Gy, the CW volume receiving approximately 35 Gy should be limited to <55 cc in our regimen. Our study found that HT was able to prevent the CW receiving 35 Gy even in patients considered to be at risk of developing CW pain and/or rib fractures as defined by lesions within 2.5 cm of the CW receiving a >20 Gy maximal point dose to the adjacent CW. On the other hand, we were concerned about pulmonary complications due to HT, because it is considered that the normal lung volume of HT tends to be higher than that of Linac-based SRT because of its helical beam trajectory. Pulmonary complications of Grade 2 were observed in two patients, and one of these patients experienced Grade 5 radiation pneumonitis. The MLD was significantly correlated with pulmonary complications Grade 2 in our study (p = 0.030). This result was consistent with the recent study by Borst et al., in which a significant dose-response relationship between the risk of RP and MLD for SRT (32). In the Borst study, MLD was modeled by a sigmoid-shaped relation using the TD 50 representing the dose for a 50% complication probability. HT in cases in which a severe pulmonary toxicity is predicted from the high MLD, especially in cases which have a severe pulmonary comorbidity. Although the normal lung volumes receiving any doses are usually correlated with mean lung dose, no lung dosimetric parameter was correlated with pulmonary toxicity except mean lung dose in our study. We think that this might be due to the small sample size of 12.
There has been some concern that organ motion, especially intra-fraction organ motion due to breathing, can negate the potential merit of IMRT. Previous theoretical and simulation studies reported that the effect of respiratory motion on statically planned tomotherapy treatments can cause substantial differences between the calculated and delivered radiation isodose distributions, particularly when the treatment is hypofractionated. Bortfeld et al., concluded in their simulation that the main effect of organ motion in IMRT is an averaging of the dose distribution without motion over the path of the motion (33). In the light of this, we divided 10 Gy per day into 5 Gy fractions with no interval between the fractions. On the other hand, Kanagaki et al., performed phantom film dosimetry measurements under static and moving conditions using a clinical HT treatment unit to determine the dosimetric effects of motion upon HT treatment delivery (34). They concluded that HT is a safe technique that is suitable for treating moving targets and hypofractionation. An additional concern of HT for a lung tumor is that it is currently capable of only coplanar treatment, which results in less ability to spread the exit and entrance dose outside the radial plane compared to noncoplanar treatment methods. This suggested that the normal lung volumes covered by low dose could be higher in HT plan than in noncoplanar treatment plans. However, our study and other HT studies (29) (30) (31) found that the DVH of the normal lung volumes were acceptable.
In conclusion, HT is a feasible non-invasive technique for treating solitary lung tumors, and acheives high accuracy in terms of its dose conformity and homogeneity. Its local tumor control rate is comparable with those of other SRT techniques allowing a higher dose to be administered without increasing the risk of complications. We are currently conducting a prospective phase II study of stereotactic body radiation therapy using helical tomotherapy for stage IA non-small cell lung cancer (35).
